Skip to Content
Merck
  • Ubiquinone, dolichol, and cholesterol metabolism in aging and Alzheimer's disease.

Ubiquinone, dolichol, and cholesterol metabolism in aging and Alzheimer's disease.

Biochemistry and cell biology = Biochimie et biologie cellulaire (1992-06-01)
C Edlund, M Söderberg, K Kristensson, G Dallner
ABSTRACT

The lipid compositions of various regions of the human brain were investigated during aging and in Alzheimer's disease. The phospholipid amounts and compositions remained unchanged during aging. There were, however, considerable differences both in phospholipid composition and amount when the various regions were compared. The level of dolichol increased severalfold in all regions up to the age of 70, but there was no further elevation thereafter. The ubiquinone level decreased significantly in all parts of the brain upon aging. In Alzheimer's disease, the dolichol level was decreased in all regions, and particularly, in those affected by the disease. In contrast, the dolichyl-P concentration increased in those regions that exhibited morphological changes. There was no modification in cholesterol distribution, but a significant elevation in ubiquinone content was observed in most regions. The only phospholipid whose level was elevated was phosphatidylinositol, and only in those parts of the brain that were affected. The content of polyunsaturated fatty acids in phosphatidylethanolamine was greatly decreased in connection with the disease, with a parallel increase in the saturated portion. The results indicate that Alzheimer's disease results in specific and significant changes in the levels of lipid products of the mevalonate pathway in the brain.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Coenzyme Q1, ≥95%